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The Src homology 2 domain-containing protein-tyrosine phosphatase Src homology phosphatase
2 (Shp2) is a negative regulator of hepatic insulin action in mice fed regular chow. To investigate
the role of hepatic Shp2 in lipid metabolism and energy balance, we determined the metabolic
effects of its deletion in mice challenged with a high-fat diet (HFD). We analyzed body mass, lipid
metabolism, insulin sensitivity, andglucose tolerance in liver-specific Shp2-deficientmice (referred
to herein as LSHKO) and control mice fed HFD. Hepatic Shp2 protein expression is regulated by
nutritional status, increasing in mice fed HFD and decreasing during fasting. LSHKO mice gained
less weight and exhibited increased energy expenditure compared with control mice. In addition,
hepatic Shp2 deficiency led to decreased liver steatosis, enhanced insulin-induced suppression of
hepatic glucose production, and impeded the development of insulin resistance after high-fat
feeding. At the molecular level, LSHKO exhibited decreased hepatic endoplasmic reticulum stress
and inflammation compared with control mice. In addition, tyrosine and serine phosphorylation
of total and mitochondrial signal transducer and activator of transcription 3 were enhanced in
LSHKO compared with control mice. In line with this observation and the increased energy ex-
penditure of LSHKO, oxygen consumption rate was higher in liver mitochondria of LSHKO com-
pared with controls. Collectively, these studies identify hepatic Shp2 as a novel regulator of sys-
temic energy balance under conditions of high-fat feeding. (Endocrinology 153: 3158–3169, 2012)
Obesity is a major health problem worldwide, andobese individuals exhibit a higher risk of chronic dis-
eases, such as cardiovascular disease, nonalcoholic fatty
liver disease (NAFLD), and type 2 diabetes mellitus (1–3).
Currently, there are few therapies for targetingobesity and
its associated comorbidities in humans. Thus, elucidating
themechanismsunderlyingobesity is vital for understand-
ing its pathogenesis and developing effective therapies.
Genetic and molecular studies identified tyrosine phos-
phorylation as a key regulator of energy balance and glu-
cose homeostasis (4–6).
Tyrosine phosphorylation is tightly controlled by the
opposing actions of protein-tyrosine kinases and protein-
tyrosine phosphatases (PTP) (7). Src homology phospha-
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tase 2 (Shp2) is a broadly expressed nontransmembrane
PTP that plays an essential role in most receptor tyrosine
kinase signaling pathways (8–10). In vivo studies pro-
vided insights into the physiological role of Shp2 in insulin
signaling and glucose homeostasis. Targeted mutation of
Shp2 exon 3 in mice leads to embryonic lethality (11),
precluding studies of the effects of global Shp2 deletion.
Hemizygous mice are viable but do not manifest any ap-
parent defects in insulin action (12). Transgenic mice that
express a dominant negative mutant of Shp2 in skeletal
muscle, liver, and adipose tissue exhibit insulin resistance
and impaired insulin-stimulated glucose uptake (13). In
addition, Shp2 deletion in striated and cardiac muscle re-
sults in insulin resistance, impaired glucose uptake inmus-
cle cells, and glucose intolerance (14, 15).Moreover, Shp2
deletion in the pancreas causes defective glucose-stimu-
lated insulin secretion and impaired glucose tolerance
(16). On the other hand, mice lacking Shp2 in the liver
exhibit increased hepatic insulin action and enhanced sys-
temic insulin sensitivity (17). The improved insulin sensi-
tivity is caused, at least in large part, by attenuation of
direct dephosphorylation of insulin receptor substrate 1/2
in the liver and concomitant increase in phosphatidylino-
sitol 3 kinase/Akt signaling (17).
Shp2 has been implicated in energy balance and body
mass regulation (18, 19). In vitro studies reveal that Shp2
promotes signaling from Tyr985 of the leptin receptor,
leading to enhanced activation of the Erk pathway (20,
21). These findings are supported by studies in mice with
selective deletionof Shp2 inpostmitotic forebrain neurons
that develop leptin resistance and early onset obesity (22).
In addition, another line of neuronal Shp2 deletion also
exhibits obesity and insulin resistance (23). Moreover,
mice with proopiomelanocortin neuron-specific Shp2 de-
letion exhibit decreased leptin sensitivity and elevated ad-
iposity, implicating Shp2 as an important component of
proopiomelanocortin neuron regulation of energy bal-
ance (24). Together, these studies highlight the function of
neuronal Shp2 in energy balance. However, the role of
Shp2 in peripheral tissues in systemic energy balance, if
any, remains to be determined.
In this study, we investigated the metabolic effects of
hepatic Shp2 deficiency in mice challenged with high-fat
feeding. We determined alterations in body mass, energy
balance, glucose homeostasis and lipid metabolism and
delineated the underlying molecular mechanisms.
Materials and Methods
Mouse studies
Shp2 floxed (Shp2fl/fl) mice were generated previously (25).
Albumin-Cre mice were obtained from C. R. Kahn (Joslin Dia-
betes Center/Harvard University, Boston,MA). All mice studied
were age-matched males on a mixed 129Sv/J x C57Bl/6J back-
ground and were maintained on a 12-h light, 12-h dark cycle
with free access to water and food. Mice were fed standard lab
chow (no. 5001; Purina, St. Louis,MO)atweaning and switched
tohigh-fatdiet (HFD) (60%kcal fromfat, no.D12492;Research
Diets, New Brunswick, NJ) at 6 wk of age. Genotyping for the
Shp2 floxed allele and for the presence of Cre was performed by
PCR,usingDNAextracted fromtails (17).Micewere euthanized
by cervical dislocation, and the liver, spleen, kidney, heart, pan-
creas, epididymal, retroperitoneal, mesenteric, subcutaneous,
and brown adipose depots were collected and weighed. A por-
tion of each liverwas snap frozen in liquid nitrogen for biochem-
ical studies while another portionwas fixed in buffered formalin
for hematoxylin-eosin (H&E) staining. All mouse studies were
approved by the Institutional Animal Care and Use Committee
at University of California Davis.
Metabolic measurements
Biochemical parameters, energy expenditure, mitochondrial
oxygen consumption rates, assessment of insulin sensitivity and
glucose tolerance, and hyperinsulinemic-euglycemic clamps
were performed as detailed in Supplementary Methods, pub-
lished on The Endocrine Society’s Journals Online web site at
http://endo.endojournals.org.
Biochemical analyses
Forbiochemical studies, 32-wk-oldmalemice fedHFDfor26
wkwere fasted overnight and then killed. Tissueswere ground in
liquid nitrogen and lysed using radioimmunoprecipitation assay
buffer aswe previously described (17). Proteinswere resolved by
SDS-PAGE and transferred to polyvinylidene fluoride mem-
branes. Immunoblot of lysates was performed with primary an-
tibodies (Supplemental Table 1), and after incubation with ap-
propriate secondary antibodies, proteins were visualized using
chemiluminescence (Bio-Rad, Hercules, CA). Pixel intensities of
immunoreactive bands were quantified using FluorChem 9900
(Alpha Innotech, Santa Clara, CA). Expression of lipogenic
genes was assessed by quantitative real-time PCR (iCycler; Bio-
Rad)usingSYBRGreenwithappropriateprimers (Supplemental
Table 2) as we described previously (17).
Statistical analyses
Data are expressed as mean  SEM. Statistical analyses were
performedusing JMP8software (SAS Institute,Cary,NC).Com-
parisons between groups weremade by unpaired two-tailed Stu-
dent’s t test. A symbol (*) indicatesP0.05,whereas a duplicate
symbol (**) indicates P 0.01. Insulin tolerance tests (ITT) and
glucose tolerance tests (GTT) were analyzed by repeated mea-
sures ANOVA. Post hoc analysis was performed using Tukey-
Kramer honestly significant difference test.
Results
Nutritional regulation of hepatic Shp2 expression
Hepatic Shp2 deficiency alters glucose homeostasis in
mice fed regular chow (17). To further investigate themet-
abolic functions of hepatic Shp2, we challengedmice with
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prolonged (26 wk) high-fat feeding. Subsequently, we de-
termined alterations in hepatic inflammation, endoplas-
mic reticulum (ER) stress, and Shp2 expression. Consis-
tent with published studies (26, 27), immunoblots of liver
lysates revealed increased hepatic TNF expression in
wild-type mice fed HFD compared with those fed regular
chow, suggesting elevated inflammatory response (Fig.
1A). In addition, binding immunoglobulin protein expres-
sion was increased in mice fed HFD compared with those
fed regular chow, suggesting increased ER stress response.
Notably, Shp2 expression was elevated (2-fold) in livers
of mice fed HFD compared with those fed regular chow.
Similarly, expression of another PTP known to regulate
hepatic insulin signaling, PTP1B (28), was increased in
mice fed HFD (Fig. 1A). Next, we investigated the effects
of fasting and refeeding on hepatic Shp2 expression. Shp2
protein expression decreased in the livers of fasted mice
but returned to control (fed) levels upon refeeding (Fig.
1B). In line with published reports (29, 30), fasting led to
increased hepatic peroxisome proliferator-activated re-
ceptor  coactivator-1 (PGC1) and decreased PTP1B
expression. Together, these findings demonstrate that he-
patic Shp2 expression is regulated by nutritional status in
mice.
Given the nutritional regulation of hepatic Shp2 ex-
pression, we generated mice with liver-specific Shp2 de-
letionaswepreviouslydescribed (17) andchallenged them
with HFD. Briefly, albumin-Cre Shp2fl/ mice were
crossed to Shp2fl/fl mice, yielding Alb-Cre Shp2fl/fl [liver-
specific Shp2 knockout (LSHKO)], Alb-Cre Shp2fl/
[heterozygous (HET)], and Shp2fl/fl (control; fl/fl) mice.
Immunoblot analysis of liver lysates from mice fed HFD
indicated that Shp2 protein expression was decreased by
approximately 55% in HET and approximately 85% in
FIG. 1. Nutritional regulation of hepatic Shp2 protein expression. A, Immunoblot of TNF, binding immunoglobulin protein (BiP), Shp2, and
PTP1B expression in liver lysates of wild-type male mice (32 wk old) fed regular chow and HFD (for 26 wk). Lysates were also probed for tubulin as
a loading control. Each lane represents liver lysates from a different animal. Bar charts represent Shp2 and PTP1B protein expression normalized to
tubulin. B, Immunoblot of Shp2, PTP1B, and PGC1 in liver lysates of male mice (34 wk old) that were fed regular chow ad libitum (fed), fasted for
24 h (fasted), or fasted for 24 h followed by 14 h of feeding (refed). Bar charts represent Shp2, PTP1B, and PGC1 protein expression normalized
to tubulin. C, Immunoblot of Shp2 expression in various tissues from Shp2fl/fl (fl/fl), Alb-Cre Shp2fl/ (HET), and Alb-Cre Shp2fl/fl (LSHKO) mice. Bar
chart represents hepatic Shp2 expression normalized to tubulin. Data were analyzed by two-tailed Student’s t test, and results represent mean 
SEM. *, Significant difference between chow and HFD (A), fasted and fed (B), and HET and LSHKO vs. fl/fl (C).
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LSHKO compared with control (Fig. 1C). This is consis-
tent with complete deletion of Shp2 in hepatocytes, and
the residual expression is likelydue to thepresenceofother
cell types in the liver as we previously indicated (17). Shp2
expression was unchanged in muscle, adipose tissue, and
brain (hypothalamus, cerebellum, and cerebral cortex),
indicating specificity of deletion. Thus, LSHKOmice pro-
vide a useful tool to dissect the effects of hepatic Shp2
deficiency on HFD-induced metabolic damage.
Decreased body weight and adiposity in LSHKO
mice fed HFD
To investigate whether hepatic Shp2 deficiency affects
systemic energy balance, we determined body weights of
mice fedHFD. Bodyweights of LSHKOwere significantly
lower than those of control mice, and by the end of the
study, LSHKOmice weighed 12% less than controls (Fig.
2A). Similar findings were observed in three other inde-
pendent cohorts of mice (data not shown). In addition,
food intakewas comparable betweenLSHKOand control
mice fed HFD (Supplemental Fig. 1A). Moreover, bomb
calorimetry revealed a trend for decreased energy in feces
of LSHKO compared with control mice, suggesting pos-
sible increase in intestinal absorption in LSHKO mice
(Supplemental Fig. 1B). To determine the tissue(s) that
contributes to decreased bodyweight in LSHKOmice, we
performed body composition analysis. Liver, mesenteric,
and subcutaneous fat depots andkidneyweights (adjusted
to body weight) were significantly lower in LSHKO com-
pared with control mice (Fig. 2B). In line with decreased
fat mass, LSHKO exhibited lower leptin concentrations
comparedwith controlmice (Table 1). Although Shp2 has
been implicated in growth hormone signaling (31), com-
parable head-rump length and hepatic IGF-I mRNAwere
observed in LSHKO and control mice, suggesting no al-
terations in growth hormone signaling (Supplemental Fig.
1, C and D).
To investigate the mechanism underlying decreased
body weight of LSHKO mice, we determined energy ex-
penditure of 27-wk-old LSHKOand controlmice in open-
circuit indirect calorimetry cages as described in Supple-
FIG. 2. Decreased body weight and increased energy expenditure in LSHKO mice fed HFD. A, Body weights of fl/fl (n  8) and LSHKO (n  9)
mice fed HFD from 6 wk of age. B, Tissue weight is presented as percentage of body weight. Energy expenditure (C), respiratory quotient (D), and
total activity (E) in fl/fl (n  8) and LSHKO (n  8) mice during dark and light cycles. Bar graphs of energy expenditure and respiratory quotient
represent AUC calculations. F, Average rectal temperature in fl/fl (n  7) and LSHKO (n  7) mice at 23 wk of age measured in three consecutive
days. Data were analyzed by two-tailed Student’s t test, and results represent the mean  SEM. *, Significant difference between fl/fl and LSHKO.
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mental Methods. Energy expenditure was significantly
elevated in LSHKO compared with control mice, partic-
ularly during the dark cycle, when mice are more active
and the thermic effect of food is highest (Fig. 2C). In ad-
dition,LSHKOexhibiteda trend fordecreased respiratory
quotient (Fig. 2D), and increased locomotor activity (Fig.
2E) compared with control mice, but these did not reach
statistical significance. Consistent with their increased en-
ergy expenditure, LSHKOdisplayed a significant increase
in body temperature compared with control mice (Fig.
2F). Together, these findings indicate that the decreased
body weight of LSHKO mice fed HFD is due, at least in
part, to increased energy expenditure.
Hepatic Shp2 deficiency reduces steatosis, ER
stress, and inflammation in mice fed HFD
HFD causes accumulation of lipids in the liver, a pro-
cess that leads to fatty liver disease (also known as NA-
FLD) and eventually to nonalcoholic steatohepatitis (32).
H&Estaining of liver sections of controlmice fedHFD for
26 wk revealed micro- and macrosteatosis (Fig. 3A). In
contrast, LSHKOmice presented with a lower number of
TABLE 1. Metabolic parameters of fl/fl and LSHKO
mice fed HFD for 8 wk
Metabolic parameters fl/fl (n  8) LSHKO (n  8)
Blood glucose (mg/dl)
Fed 179.4  6.2 143.1  7.6b
Fasted 116.3  14.6 88.4  4.3
Serum insulin (ng/ml)
Fed 3.38  1.30 1.65  0.31
Fasted 0.34  0.11 0.17  0.03
Leptin (ng/ml) fed 93.2  14.1 46.0  5.7a
Free fatty acids (mM) fed 0.38  0.03 0.31  0.01a
Statistical analysis was performed using unpaired, two-tailed Student’s
t test.
a Difference between fl/fl and LSHKO mice; *, P  0.05.
b Difference between fl/fl and LSHKO mice; **, P  0.01.
FIG. 3. Decreased liver steatosis and dyslipidemia in LSHKO mice fed HFD. A, Liver sections from fl/fl and LSHKO mice fed HFD at 32 wk of age
were analyzed by H&E staining. Boxed regions in the upper panel are magnified in lower panel. Scale bars, 100 m. B, Hepatic triglyceride and
cholesterol of fl/fl (n  8) and LSHKO (n  8) mice. C, Serum triglyceride and cholesterol were measured at 14 wk of age. D, Quantitative real-
time PCR determination of mRNA of genes implicated in fatty acids (FA) synthesis, oxidation, uptake, and very low-density lipoprotein (VLDL)
secretion (normalized against 36B4) in livers of fl/fl (n  8) and LSHKO (n  8) mice. Total RNA was extracted from the same liver samples used for
lipids measurement. Results represent the mean  SEM and were analyzed by two-tailed Student’s t test. *, Significant difference between fl/fl and
LSHKO. PPAR, peroxisome proliferator-activated receptor ; CPT1a, carnitine palmitoyltransferase 1a; MTTP, microsomal triglyceride transfer
protein; FATP5, fatty acid transporter member 5; TG, triglyceride.
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lipid droplets and with small diameter. Consistent with
this observation, liver triglyceride content was signifi-
cantly lower in LSHKO compared with control mice (Fig.
3B) and comparable with LSHKO mice fed regular chow
(77.7 8.4 mg/g liver) as we previously reported (17). In
addition, liver cholesterol content tended to be lower in
LSHKO compared with control mice but did not reach
statistical significance (Fig. 1B). Serum triglyceride, cho-
lesterol, and free fatty acid concentrations were signifi-
cantly lower in LSHKO compared with control mice (Fig.
3C and Table 1). Consistent with histological findings,
hepatic mRNA of lipogenic genes, such as sterol regula-
tory element binding protein (SREBP)-1c and stearoyl-
Coenzyme A desaturase 1, was significantly lower in
LSHKO compared with control mice (Fig. 3D). However,
mRNA of genes for -oxidation, such as peroxisome pro-
liferator-activated receptor  and carnitine palmitoyl-
transferase 1a, and genes for very low-density lipoprotein
secretion, such as microsomal triglyceride transfer pro-
tein, was comparable in the livers of LSHKO and control
mice. On the other hand, hepatic mRNA of fatty acid
transporter member 5, exclusively expressed in the liver,
was significantly increased in LSHKO compared with
control mice possibly due to compensation for decreased
de novo fatty acids synthesis. We further investigated
whether hepatic Shp2 deficiency mitigates HFD-induced
ER stress and inflammation. Cells use adaptive mecha-
nisms tomitigate ER stress known as the unfolded protein
response (33). Unfolded protein response is triggered by
proteins on the ER: protein kinase RNA-dependent-like
ER-regulated kinase, inositol-requiring protein 1, and
activating transcription factor 6 (34). If the adaptive
mechanisms fail to preserve homeostasis, then this will
lead to inflammation and hepatosteatosis (35, 36). In ad-
dition, a major mediator of metabolic dysfunction in ad-
iposity is cellular inflammation, and up-regulation of in-
flammation is detrimental to proper insulin signaling (37).
Immunoblot analyses of liver lysates revealed significant
reduction in hepatic ER stress and inflammation markers
in LSHKO compared with control mice (Supplemental
Fig. 2). Together, these findings indicate that hepatic Shp2
deficiency mitigates HFD-induced steatohepatitis and
might confer protection against the development of
hyperlipidemia.
LSHKO mice are protected against HFD-induced
insulin resistance
Mice with acute or chronic hepatic Shp2 deletion fed
regular chow exhibit increased insulin sensitivity com-
pared with controls without alterations in body weight
(17). To further examine the effects of hepatic Shp2 defi-
ciency on glucose homeostasis, we tested whether its de-
letion mitigates HFD-induced insulin resistance. We as-
sayed several metabolic parameters in LSHKO and
control mice (Table 1). LSHKO exhibited significantly
lower fed blood glucose, and a trend toward decreased
fasting glucose compared with control mice suggesting
increased insulin sensitivity. Consistent with this obser-
vation, LSHKO mice exhibited a trend toward decreased
fed and fasted serum insulin concentrations, although
these did not reach statistical significance. These data sug-
gest that LSHKO have increased systemic insulin sensitiv-
ity compared with control mice. To directly assess insulin
sensitivity, mice were subjected to ITT at different stages
of high-fat feeding. LSHKOexhibited significantly greater
reduction in blood glucose after insulin injection com-
pared with control mice [area under the curve (AUC), fl/fl
10,059632 vs.LSHKO7112345%Xmin;P0.01]
(Fig. 4A). In addition, LSHKO mice showed increased
ability to clear glucose from theperipheral circulationdur-
ing GTT (AUC, fl/fl 35,987 2174 vs. LSHKO28,558
1599 mg/dlmin; P  0.02) (Fig. 4B). Comparable differ-
ences were preserved in older (20 wk old) mice (AUC in
ITT: fl/fl 7775  461 vs. LSHKO 6110  544% X min,
P  0.04; AUC in GTT: fl/fl 39,353  2343 vs. LSHKO
31,583  1865 mg/dlmin, P  0.02) (Supplemental Fig.
3, A and B). There was no significant difference in insulin
secretion between LSHKO and control mice during GTT
(data not shown). In linewith increased insulin sensitivity,
LSHKO exhibited enhanced insulin-induced hepatic Akt
Ser473 phosphorylation compared with control mice
(Supplemental Fig. 3C).
To gain further insight into the underlying mechanism
of enhanced insulin sensitivity, we performed hyperinsu-
linemic-euglycemic clamps in LSHKO mice fed HFD for
14 wk. Basal hepatic glucose production (HGP) was not
different in control and LSHKO mice. However, insulin
failed to suppress HGP during the clamp in control mice,
consistent with the severe hepatic insulin resistance
evoked by chronic high-fat feeding (Fig. 4C). In contrast,
HGP was almost completely suppressed in LSHKO mice
during clamps (insulin-stimulated state), resulting in
higher insulin-mediated suppression of HGP in LSHKO
mice (Fig. 4,C andD).Moreover, the glucose infusion rate
required tomaintain euglycemiaduring clampswashigher
in LSHKO mice, suggesting an improvement in whole-
body insulin response (Fig. 4E). Insulin-stimulatedwhole-
body glucose turnover was similar in the two groups, in-
dicating no difference in glucose uptake between control
and LSHKO mice (Fig. 4F). Whole-body glycogen and
lipid synthesis and whole-body glycolysis also were com-
parable between the two groups (Supplemental Fig. 3, D
and E). As expected from our study, blood glucose tended
to be lower in LSHKO mice under basal conditions, but
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this difference did not reach statistical significance (Sup-
plemental Fig. 3F). However, circulating insulin was sig-
nificantly lower inLSHKOmice at baseline (Supplemental
Fig. 3G).Taken together, these findings reveal that hepatic
Shp2 deficiency attenuates the development of HFD-in-
duced insulin resistance.
Increased hepatic signal transducer and activator
of transcription 3 (STAT3) phosphorylation in HFD-
fed LSHKO mice
To delineate the molecular basis for increased energy
expenditure in LSHKO mice, we assessed STAT3 phos-
phorylation. Shp2 was implicated in regulating STAT3
(Tyr705) phosphorylation in mouse heart (15) and liver
(38). Of note, STAT3 is activated by phosphorylation at
Tyr705, leading to its dimerization and relocation to the
nucleus to promote gene expression (39). In addition,
phosphorylation at Ser727 is required for maximal tran-
scriptional activity of STAT3 (40, 41). Importantly,
STAT3 Ser727 phosphorylation is required for its mito-
chondrial actions and regulation of oxidative phosphor-
ylation (41, 42). Immunoblot of liver lysates from fasted
mice revealed that STAT3 (Tyr705) phosphorylation,
normalized to STAT3 expression, was increased in
LSHKO compared with control mice (Fig. 5A), consistent
with published data (15, 38). Moreover, STAT3 (Ser727)
phosphorylation was increased in liver lysates of LSHKO
compared with control mice. We further investigated
STAT3 phosphorylation inmitochondrial fractions of the
liver (Fig. 5B).Mitochondrial STAT3 (Ser727) phosphor-
ylation was significantly increased in LSHKO compared
with control mice, and Shp2 was detected in liver mito-
chondria as previously reported (43).
STAT3 (Ser727) can be phosphorylated by several ki-
nases, such as Erk, c-Jun N-terminal kinase (JNK), mam-
malian target of rapamycin/p70S6K, and protein kinase
C (PKC) (40, 44). Thus, we examined whether these
serine kinases were implicated in the elevated STAT3
(Ser727) phosphorylation in LSHKO mice. Immunoblot
analysis revealed that p-ERK (Thr202/Tyr204) and
p-JNK (Thr183/Tyr185) were significantly decreased in
LSHKO compared with control mice (Fig. 5C). In addition,
phosphorylation of p70S6K (Thr389) and its substrate S6
ribosomal protein (Ser235/236) were comparable between
LSHKO and control mice at fasted conditions. In contrast,
FIG. 4. Improved insulin sensitivity and glucose tolerance in LSHKO mice fed HFD. A, ITT (0.7 mU/g body weight) on fl/fl (n  8) and LSHKO (n 
7) mice fed HFD at 9 wk of age. Data are expressed as percentage change of initial value. B, GTT (1.2 mg/g body weight) on fl/fl (n  8) and
LSHKO (n  8) mice at 12 wk of age. Results represent the mean  SEM, and data were analyzed by repeated measures ANOVA and Tukey-Kramer
honestly significant difference test. C–F, Hyperinsulinemic-euglycemic clamps were performed on fl/fl (n  5) and LSHKO (n  5) mice fed HFD. C,
HGP under basal and clamp conditions. D, Insulin-mediated percent suppression of HGP. E, Glucose infusion rate during clamps. F, Insulin-
stimulated whole-body glucose turnover. Statistical analysis was performed using one-tailed Student’s t test. *, Significant difference between fl/fl
and LSHKO mice.
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phosphorylation of PKC (Thr505), which is important
for catalytic activity (45), was significantly increased in
LSHKO compared with control mice (Fig. 5D). Together,
these findings demonstrate elevated phosphorylation of
total and mitochondrial STAT3 in LSHKOmice and sug-
gest that this might contribute to increased energy
expenditure.
Increased mitochondrial respiration in HFD-fed
LSHKO mice
STAT3 (Ser727) phosphorylation is required for
STAT3mitochondrial actions and regulation of oxidative
phosphorylation (41, 42). To test whether increased
STAT3 (Ser727) phosphorylation in LSHKO mice con-
tributes to mitochondrial respiratory function, we mea-
sured oxygen consumption rate in liver mitochondria of
LSHKO and control mice using the Seahorse XF24 ana-
lyzer. When pyruvate/malate was used to determine com-
plex I-driven respiration, ADP-stimulated (state III) res-
piration rates were significantly increased (20%) in
LSHKO compared with control mice (Fig. 6A). The max-
imal respiratory capacity was comparable, and reserve re-
spiratory capacity tended to be lower in LSHKO com-
pared with control mice but did not reach statistical
significance (Fig. 6A). On the other hand, succinate-in-
duced state III respiration, which represents complex II-
driven respiration, maximal respiratory capacity, and re-
serve capacity, was not changed by hepatic Shp2
deficiency (Fig. 6B). In addition, LSHKO exhibited a sig-
nificantly increased capacity for complex III-linked reac-
tive oxygen species production compared with control
mice, because reactive oxygen spices production was not
increased in these mice when complex I was fully reduced
(pyr/mal  rotenone) but was observed when both com-
plex I and III were reduced (pyr/mal  antimycin A and
FIG. 5. Increased hepatic STAT3 phosphorylation in LSHKO mice fed HFD. Immunoblots of p-STAT3 (Tyr705 and Ser727), STAT3, Shp2, and
tubulin in liver lysates of fasted mice (A) and isolated liver mitochondria (B). Mitochondrial proteins were also probed for cytochrome c oxidase
subunit IV (COXIV) and tubulin to check the purity of the samples. Immunoblot analysis of p-ERK (Thr202/Tyr204), ERK, p-JNK (Thr183/Tyr185),
JNK, p-p70S6K (Thr389), p70S6K, and p-S6 (Ser235/236) (C) and p-PKC (Thr505) and PKC (D) using liver lysates. Each lane represents liver
lysates from a different fasted animal. Bar graphs represent normalized data for p-STAT3/STAT3, p-ERK/ERK, p-JNK/JNK, p-S6/Erk,
p-p70S6K/p70S6K, and p-PKC/PKC from two independent experiments and presented as mean  SEM. Statistical analysis was performed using
two-tailed Student’s t test. *, Significant difference between fl/fl and LSHKO mice. A.U., Arbitrary unit.
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succinate  antimycin A) (Supplemental Fig. 4). Addi-
tional studies are required to further delineate the regula-
tion of mitochondrial function by Shp2. Together, these
data demonstrate that hepatic Shp2modulates mitochon-
drial function, including respiration and electron trans-
port in the liver ofmice fedHFD, and this may contribute,
at least in part, to the increased energy expenditure in
LSHKO mice.
Discussion
Obesity is a leading cause of several debilitating diseases,
such as type 2 diabetes mellitus and NAFLD (1–3). To
develop effective therapies for these diseases, it is impor-
tant to elucidate the underlyingmolecularmechanisms. In
this study, we report that hepatic Shp2 deficiency miti-
gated HFD-induced metabolic damage. LSHKOmice fed
HFD gained less weight than controls and exhibited de-
creased liver steatosis. In addition, hepatic Shp2deficiency
impeded the development of HFD-induced insulin resis-
tance. At the molecular level, LSHKO mice exhibited de-
creasedhepaticERstress and inflammation, and increased
STAT3 phosphorylation compared with controls. Collec-
tively, these findings demonstrate a novel role for hepatic
Shp2 in metabolic homeostasis and systemic energy
balance.
Hepatic Shp2 expression is dynamically regulated by
nutritional status inmice, increasingwith high-fat feeding
and decreasing during fasting. The underlying reason(s)
for this regulation remain to be determined but is likely to
involve several factors, such as insulin sensitivity and/or
inflammation, among others. Previous studies demon-
strate that Shp2 expression and activity are increased in
livers of diabetic rats (46). However, factors other than
insulin resistance can also regulate PTP expression in vivo.
Indeed, inflammation is a contributing factor underlying
PTP1Boverexpression indiabetes andobesity in vivo (47).
Given the role of Shp2 in regulatingTNFreceptor and IL-6
signaling (48), HFD-induced inflammatory responses
might contribute to hepatic Shp2 overexpression. Impor-
tantly, the increased expression of Shp2 after high-fat
feeding raises the possibility that hepatic Shp2 inhibition/
FIG. 6. Increased oxygen consumption rate in isolated mitochondria from liver of LSHKO mice fed HFD. A, Bioenergetic profile of isolated liver
mitochondria from LSHKO and fl/fl (n  6 per group) mice fed HFD at 32 wk of age using pyruvate as the substrate in presence of malate. State III
respiration was induced by ADP, proton leak-driven respiration was accessed by oligomycin, and respiratory capacity was measured as carbonyl
cyanide-p-trifluoromethoxyphenylhydrazone (FCCP)-induced respiration. Bar graphs represent oxygen consumption rate (OCR) for indicated rates
of oxygen consumption; 7.5 g of protein were used per well. B, Bioenergetic profile of mitochondria was assayed by using succinate as the
substrate in the presence of rotenone; 5 g of protein were used per well. Each mouse liver was assayed in pentaplicate. Statistical analysis was
performed using two-tailed Student’s t test (*, P  0.05).
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deficiency might protect against HFD-induced metabolic
damage, as demonstrated by the current study. Additional
studies are required to fully elucidate the mechanism(s) un-
derlying nutritional regulation of hepatic Shp2 expression.
Mice with hepatic Shp2 deficiency gained less weight
on HFD compared with controls. This was due, in large
part, to increased energy expenditure in LSHKOmice. At
the molecular level, the increased hepatic STAT3 phos-
phorylation in LSHKOmice could contribute to their sys-
temic energy expenditure. Hepatic STAT3 deletion leads
to insulin resistance and increased adiposity and body
weight (49). In addition, STAT3 (Ser727) phosphoryla-
tion is required for STAT3 mitochondrial actions, where
it promotes the activity of electron transport chain that
generates energy by oxidative phosphorylation (41, 42).
The current data suggest that STAT3 (Ser727) phosphor-
ylation in LSHKO mice could be regulated by PKC, but
additional studies are required to elucidate the mecha-
nisms of STAT3 regulation in LSHKO mice. At any rate,
the observed biochemical alterations translate to regula-
tion of respiratory function. Increased respiration using
pyruvate as a substrate suggests that LSHKO mice liver
mitochondria have increased proton flux through com-
plex I, which is important for utilization of NADHH
produced by the tricarboxylic acid cycle and by -oxida-
tion inmitochondria (Supplemental Fig. 5). It is important
to note that we cannot rule out that the increased insulin
sensitivity in LSHKO mice contributes to their decreased
bodymass. Indeed, both PKC (Thr505) phosphorylation
and activation (50) and pyruvate dehydrogenase activity
are regulated by insulin signaling (Supplemental Fig. 5).
Finally, the contribution of extrahepatic tissues to the in-
creased energy expenditure in LSHKOmice remains to be
determined.Brownadipose tissue (BAT)and skeletalmus-
cle oxidize fatty acids through -oxidation and produce
heat by uncoupling and ATP by oxidative phosphoryla-
tion (51, 52). Expressionof uncoupling proteins and genes
involved in -oxidation, such as carnitine palmitoyltrans-
ferase 1b and medium chain acyl-coenzyme A dehydro-
genase in BAT and skeletal muscle was comparable in
LSHKOand control mice (Supplemental Fig. 6). This sug-
gests that increased energy expenditure in LSHKOmice is
unlikely due to increased uncoupling proteins expression
and -oxidation in BAT and/or skeletal muscle.
LSHKO mice fed HFD exhibited reduced hepatic ste-
atosis comparedwith controls. The current studyprovides
insights into potential underlying mechanisms that in-
clude, but are not limited to, hepatic STAT3, ER stress
signaling, and inflammation. STAT3 activation sup-
presses SREBP-1c promoter activity and decreases
SREBP-1c protein expression in hepatocytes (53–55), sug-
gesting that STAT3 activation can attenuate lipogenesis
and subsequent inflammation caused by steatosis. In line
with these reports, we demonstrated elevated hepatic
STAT3 phosphorylation and decreased mRNA of lipo-
genic genes in LSHKO compared with control mice. ER
stress has been observed in livers of murine models of
obesity (26) and patients with nonalcoholic steatohepati-
tis (56). Importantly, chemical chaperones that enhance
the ER functional capacity reduce hepatic steatosis, indi-
cating that they are useful for the treatment of NAFLD
(57). The current in vivo studies demonstrate for the first
time that hepatic Shp2 deficiency affects both eukaryotic
translation initiation factor 2 and inositol-requiring pro-
tein 1 subarms of ER stress. Finally, in obesity, inflam-
matory cytokinespromote steatosis through the inhibition
of insulin signaling andSREBP-1c activation (58, 59).Our
studies demonstrated that LSHKO mice exhibited de-
creased hepatic expression of inflammation cytokines
compared with controls. Although we cannot exclude the
possibility that decreased hepatic ER stress and inflam-
mation in LSHKO mice are secondary to decreased body
mass, our data suggest that alterations in these pathways
might account, at least in part, for the protective effects of
hepatic Shp2 deficiency against steatosis and HFD-in-
duced metabolic damage.
LSHKO mice exhibited enhanced ability of insulin to
suppress HGP, improved systemic insulin sensitivity and
glucose tolerance compared with control mice fed HFD.
The lower bodymass of LSHKOmice raises the possibility
that their improved insulin sensitivity is secondary to body
mass. However, a number of observations argue against
this notion. 1) If there was global improvement in insulin
sensitivity in response to lower body weight in LSHKO
mice on HFD, one would expect secondary increase in
muscle insulin sensitivity in these mice. However, our
clamp studies indicate that there is no increase in whole-
body glucose turnover in LSHKOmice on HFD. Further-
more, LSHKOexhibited similar basal and insulin-induced
Aktactivation (asdeterminedbySer473phosphorylation)
in skeletal muscle compared with control mice (data not
shown), suggesting no significant improvement in muscle
insulin action. 2) Previously, we reported that LSHKO
mice fed regular chow exhibited improved insulin sensi-
tivity,whereas bodyweight andbody fatwere comparable
with controls (17). 3) And similarly, improved insulin sen-
sitivity was observed in mice with adenovirus-mediated
deletion of hepatic Shp2 fed regular chow, where body
weights were comparable with controls (17). Taken to-
gether, these findings suggest that the protection against
HFD-induced insulin resistance in LSHKOmice is likely a
primary effect and not secondary to reduced bodyweight.
In summary, the current study demonstrates that he-
patic Shp2 is implicated in the regulation of lipid and glu-
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cosemetabolism and systemic energy balance. These find-
ings suggest that selective hepatic Shp2 inhibition might
have beneficial effects in the treatment of type 2 diabetes
and management of disorders associated with the meta-
bolic syndrome, including dysplipidemia and NAFLD.
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